Mark Herschel, MD
Cornea and External Diseases Specialist · Winter Park, FLNPI 1124083068
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,992 of the $6,157 with a category attached, or 64.8%. 21 manufacturers reported payments, led by Alcon at 59.0% of the total. Reporting peaked in 2019 at $2,205 and has fallen 76.6% since, to $517 in 2025.
Across 117 payments — averaging $52.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Biotissue Holdings Inc.$369
- Bausch & Lomb Americas Inc.$362
- Bausch & Lomb, A Division Of Bausch Health US, LLC$306
- Sun Pharmaceutical Industries Inc.$257
- Glaukos Corporation$209
- plus $1K from 15 others
Across 12 payments — averaging $4166.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$50K
What the payments were for
- Speaking & faculty fees$321%
- Travel & lodging$2,13235%
- Food & beverage$3,99265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 35 | $3,630 |
| Biotissue Holdings Inc. | 12 | $369 |
| Bausch & Lomb Americas Inc. | 5 | $362 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $306 |
| Sun Pharmaceutical Industries Inc. | 8 | $257 |
| Glaukos Corporation | 9 | $209 |
| Carl Zeiss Meditec, Inc. | 2 | $163 |
| Novartis | 6 | $121 |
| AbbVie(2 entities) | 7 | $102 |
| Aerie Pharmaceuticals, Inc. | 4 | $85 |
| Shire North American Group Inc | 5 | $82 |
| Dompe US, Inc. | 3 | $81 |
| Rxsight Inc | 3 | $77 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $74 |
| Oyster Point Pharma, Inc. | 2 | $53 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 2 | $39 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| Harrow Eye, LLC | 1 | $24 |
| Sight Sciences, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORA$241
- Wavelight$211
- enVista MX60 IOL$141
- XELPROS$123
- CEQUA$123
- BROMSITE$123
- ENVISTA ENVY IOL$117
- Centurion$112
- ENVISTA$112
- AKREOS MICS$112
- AcrySof IQ PanOptix UV IOL$103
- ENVISTA TORIC$100
How this compares
Too few cornea and external diseases specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 23 | $43,697 |
| RestasisCyclosporine | 12 | $20,659 |
| Prednisolone Acetate | 161 | $7,996 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $7,476 |
| Ketorolac Tromethamine | 80 | $2,140 |
| Timolol Maleate | 48 | $2,076 |
| ValacyclovirValacyclovir Hcl | 19 | $1,591 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 22 | $1,126 |
| Ofloxacin | 70 | $775 |
| Latanoprost | 55 | $712 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 40 | $395 |
| Doxycycline Hyclate | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $49 | $43,69723 claims |
| AbbVieRestasis | $102 | $20,65912 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $85 | $7,47617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Winter Park
- Priya MathewsVenice$358K
- Alfonso SabaterMiami$40K
- Leslie GarayOrlando$5K
- Ana Maria OlivaBrandon$5K
- Ansuya DeosaranBoynton Beach$3K
- Malka KirschenbaumBoynton Beach$3K
- Samantha HabhabJacksonville$3K
- Neha ShaikPalm Beach Gardens$2K
- Louis MichaelosLargo$2K
- Christopher BarronMelbourne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.